Multicenter phase IV study of palonosetron in the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with non-Hodgkin lymphomas undergoing repeated cycles of moderately emetogenic chemotherapy

Antiemetic therapy for chemotherapy-induced nausea and vomiting in patients with non-Hodgkin lymphoma (NHL) receiving moderately emetogenic chemotherapy (MEC) generally includes a serotonin-type 3 (5-HT(3)) receptor antagonist (RA). The efficacy and safety of the second-generation 5-HT(3) RA, palono...

Descripción completa

Detalles Bibliográficos
Autores principales: Choi, Brian S., Borsaru, Gabriela P., Ballinari, Gianluca, Voisin, Daniel, Di Renzo, Nicola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Informa Healthcare 2014
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3935741/
https://www.ncbi.nlm.nih.gov/pubmed/23772665
http://dx.doi.org/10.3109/10428194.2013.813498

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3935741/
https://www.ncbi.nlm.nih.gov/pubmed/23772665
http://dx.doi.org/10.3109/10428194.2013.813498

Ejemplares similares